← Back to Search

Dermal Filler

QM1114-DP for Frown Lines

Phase 3
Waitlist Available
Research Sponsored by Q-Med AB
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing QM1114-DP, a treatment to improve the appearance of wrinkles between the eyebrows and around the eyes. It works by making the skin look smoother.

Eligible Conditions
  • Crow's Feet
  • Frown Lines

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Responders in QM1114-DP versus Placebo using the Global Aesthetic Improvement Scale (GAIS) at maximum frown at Month 1
Responders in QM1114-DP versus Placebo using the Global Aesthetic Improvement Scale (GAIS) at maximum smile at Month 1

Side effects data

From 2023 Phase 3 trial • 132 Patients • NCT05146999
7%
COVID-19
6%
Headache
4%
Upper respiratory tract infection
4%
Basal cell carcinoma
3%
Sinusitis
3%
Procedural pain
2%
Contusion
2%
Fall
2%
Injection site bruising
2%
Dermatitis contact
1%
Tension headache
1%
Transient ischaemic attack
1%
Gastroenteritis viral
1%
Limb injury
1%
Hand fracture
1%
Hordeolum
1%
Influenza
1%
Postoperative wound infection
1%
Tonsillitis
1%
Wound infection
1%
Muscle strain
1%
Rib fracture
1%
Skin laceration
1%
Wrist fracture
1%
Diarrhoea
1%
Dyspepsia
1%
Irritable bowel syndrome
1%
Drug hypersensitivity
1%
Hydronephrosis
1%
Ureterolithiasis
1%
Hypertension
1%
Tooth fracture
1%
Injection site pain
1%
Conjunctivitis
1%
Oropharyngeal pain
1%
Conjunctivitis bacterial
100%
80%
60%
40%
20%
0%
Study treatment Arm
Experimental: QM1114-DP
Placebo Comparator: Placebo

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: QM1114-DPExperimental Treatment1 Intervention
QM1114-DP
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
QM1114-DP
2022
Completed Phase 3
~770

Find a Location

Who is running the clinical trial?

Q-Med ABLead Sponsor
80 Previous Clinical Trials
12,652 Total Patients Enrolled
Galderma R&DLead Sponsor
302 Previous Clinical Trials
60,662 Total Patients Enrolled
~9 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top